A U Buzdar


Affiliation: The University of Texas
Country: USA


  1. Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Res. 2015;17:56 pubmed publisher
    ..The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+ HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy. ..
  2. request reprint
    Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001;19:3357-66 pubmed
  3. Strasser Weippl K, Horick N, Smith I, O Shaughnessy J, Ejlertsen B, Boyle F, et al. Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. Eur J Cancer. 2016;56:85-92 pubmed publisher
    ..NNT in HER2+ HR- patients are in range with those reported from up-front adjuvant trastuzumab trials. ..
  4. request reprint
    Buzdar A. A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol. 2001;79:109-14 pubmed
    ..Studies in the adjuvant setting will ultimately determine whether the differences in pharmacokinetics and phamacodynamics will be of clinical relevance. ..
  5. request reprint
    Buzdar A. Clinical experience with epothilones in patients with breast cancer. Clin Breast Cancer. 2008;8 Suppl 2:S71-8 pubmed
    ..Ongoing phase II/III trials continue to assess ixabepilone and other members of the epothilone family in breast cancer, particularly in combination regimens, as being valid treatment options in multidrug-resistant breast cancer. ..